← Back to the library
InsomniaJune 26, 2023 · 3 min read

Seltorexant: An Insomniacs New Best Friend?

A clearer look at the sleep and depression research behind seltorexant, how it targets wakefulness, and where its potential fits.

Seltorexant: Sleep & Depression — What to Know, beside a blue-violet bedside scene with a pillow, clock and moonlit window
In this article

Being exhausted but unable to sleep can make an already difficult day feel even heavier. Seltorexant explores a different approach: targeting a wakefulness signal. Its ongoing research program connects two important concerns for patients—sleep and depression.12

What is seltorexant?

Seltorexant, also known as JNJ-42847922 or MIN-202, is an investigational selective orexin-2 receptor antagonist. Johnson & Johnson's current trial program includes its use alongside an existing antidepressant in adults with major depressive disorder and insomnia symptoms. That research setting is different from having an established prescription treatment for everyone who struggles with sleep.16

The original article focused on its potential for insomnia. That remains an important part of the story; the newer depression research adds another reason to pay attention.34

How it works: turning down a wakefulness signal

Orexin is part of the brain's system for maintaining wakefulness. Research on orexin circuits shows how they help sustain arousal, including through effects on sleep-promoting nerve cells. This makes the system a useful target when researchers are looking for another way to support sleep.2

An antagonist blocks a receptor's activity. Seltorexant selectively targets the orexin-2 receptor, aiming to reduce orexin-driven wakefulness. Think of it as easing the pressure to stay awake. The selectivity describes its target; its benefits and side effects still need to be understood from the trials themselves.6

What the insomnia trial found

A randomized trial published in 2025 studied 364 adults and older adults with insomnia and no psychiatric comorbidity. Participants received seltorexant, placebo or zolpidem for 14 days, with sleep measured in a laboratory.3

The 10-mg and 20-mg research groups improved both sleep initiation and sleep maintenance compared with placebo. Improvements appeared on night one and remained on night 13—encouraging findings for both falling asleep and staying asleep. The study covers two weeks, rather than years of use, and its doses are not prescribing instructions.3

Why researchers are also looking at depression

The question is broader than whether a medicine makes someone sleepy: could this approach improve depression when insomnia symptoms are also present? In a phase 3 trial, people continued an SSRI or SNRI and received seltorexant or placebo for six weeks.4

The sponsor's 2025 conference report described a 2.6-point greater average improvement in depression scores with seltorexant among participants with insomnia symptoms. The difference was statistically significant, and benefit was also found when the sleep item was removed from the depression scale. That supports looking beyond sleep alone, while recognizing that the average benefit will not describe every person's experience.4

A further 52-week open-label phase provided longer follow-up, but everyone received seltorexant, so it lacked the initial phase's placebo comparison. These results are from a sponsor-funded conference poster, distinct from a full peer-reviewed publication.4

How did it compare with quetiapine?

A separate 26-week phase 3 study compared seltorexant with quetiapine XR as additions to an antidepressant. Depression response rates were 57.4% and 53.4%, respectively, but the difference was not statistically significant. The study did not establish that seltorexant was more effective.5

The reported tolerability findings were encouraging: fewer participants stopped seltorexant because of adverse events, and average weight gain was lower. Because the primary endpoint was not met, the planned testing sequence did not formally test the weight comparison. These sponsor-reported findings point to a possible practical advantage worth further evaluation.5

Side effects and the questions that still matter

In a phase 2b depression study, commonly reported adverse events included sleepiness, headache and nausea. A different mechanism can be useful without being free of side effects.6

The insomnia trial was generally well tolerated, but some participants discontinued after electrocardiogram findings, and one seltorexant participant had a serious event. Events during treatment do not automatically establish drug causation; continued safety monitoring matters.3

What this means for someone struggling with sleep

Seltorexant's potential is hopeful because it explores a targeted approach to a problem that often overlaps with depression. It is still an investigational treatment in the current program, rather than a medicine to obtain or try on your own.1

There are options to discuss now, too. Cognitive behavioral therapy for insomnia, or CBT-I, is usually the first treatment recommended for chronic insomnia. It addresses sleep-related thoughts and behaviors and can be delivered in person, by phone or online. Medication may also have a place, depending on the situation.7

If sleep is wearing you down, bring that concern into the treatment conversation. Describe whether the difficulty is falling asleep, staying asleep or waking too early, and how it affects your days. Following new research can offer hope while you work with a clinician on support that is available today.

By Birk Gundersen, RN, BSN.

Words worth knowing

Cognitive behavioral therapy (CBT)

A structured therapy that helps people notice patterns between thoughts, feelings, and actions, then practice more helpful responses.

Insomnia

A sleep disorder involving persistent difficulty falling asleep, staying asleep, or getting restorative sleep.

References

  1. Johnson & Johnson — current phase 3 seltorexant study, NCT06559306 (investigational status; accessed October 23, 2026)
  2. De Luca et al. (2022) — experimental research on orexin circuits and maintenance of wakefulness
  3. Mesens et al. (2025) — randomized 14-day trial of seltorexant in insomnia disorder, JAMA Psychiatry
  4. Pandina et al. (2025) — phase 3 placebo-controlled results and open-label extension; sponsor-funded Psych Congress poster
  5. Flossbach et al. (2025) — phase 3 comparison with quetiapine XR; sponsor-funded Psych Congress poster
  6. Savitz et al. (2021) — phase 2b adjunctive depression study, including reported adverse events
  7. National Heart, Lung, and Blood Institute — insomnia treatment, CBT-I and medication options
Original article links (retained for continuity; not verified references for this rewrite)
Educational content—not medical advice.Find support resources →